Resistance to direct antiviral agents in patients with hepatitis C virus infection.
about
Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesisHepatitis C virus protease inhibitor-resistance mutations: our experience and reviewTreatment of chronic hepatitis C with direct-acting antivirals: The role of resistanceMechanisms of Hepatitis C Viral Resistance to Direct Acting AntiviralsResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsHCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral TherapyNanostructures for the Inhibition of Viral InfectionsFinally sofosbuvir: an oral anti-HCV drug with wide performance capabilityHepatitis C virus molecular evolution: transmission, disease progression and antiviral therapyViral quasispecies evolutionThe p7 protein of hepatitis C virus forms structurally plastic, minimalist ion channels(-)-Epigallocatechin-3-Gallate Enhances Hepatitis C Virus Double-Stranded RNA Intermediates-Triggered Innate Immune Responses in Hepatocytes.Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virusMouse Systems to Model Hepatitis C Virus Treatment and Associated ResistanceThe Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease InhibitorsHigh Affinity Peptide Inhibitors of the Hepatitis C Virus NS3-4A Protease Refractory to Common Resistant MutantsMolecular Mechanism by Which a Potent Hepatitis C Virus NS3-NS4A Protease Inhibitor Overcomes Emergence of ResistanceThe FDA-approved drug sofosbuvir inhibits Zika virus infectionA novel small molecule inhibitor of hepatitis C virus entryGenetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencingProbing of exosites leads to novel inhibitor scaffolds of HCV NS3/4A proteinaseHCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitorsEvaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevirAntiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virusA novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmissionHCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, BrazilRational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus InfectionRapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader AssayDiscovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and DockingGenetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European DatabankHigh-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsInterferon-α improves phosphoantigen-induced Vγ9Vδ2 T-cells interferon-γ production during chronic HCV infectionAn IL28B genotype-based clinical prediction model for treatment of chronic hepatitis CSerum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B proteinAn update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.Cell-cell contact-mediated hepatitis C virus (HCV) transfer, productive infection, and replication and their requirement for HCV receptors.Frontiers in the treatment of hepatitis C virus infection.Novel permissive cell lines for complete propagation of hepatitis C virus.Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir
P2860
Q21132564-1BFBE456-B531-4834-AA11-A94EF1F5A441Q24628717-9E79897C-0424-412A-9D61-BC43FBD9D74BQ26740219-7BEAA938-A820-4D96-99EF-F1D8AE0DA017Q26773321-287441B1-771E-42F3-8EE1-99AD46ECAFB8Q26777408-C69D7C13-C617-49DC-9FC0-0B48EFDCA8D1Q26782405-3C45D74C-2365-4AD2-BA94-F500B558178AQ26801513-19BFCA54-87E4-4687-8AC8-43DB8E238A3EQ26822400-B456E69F-4CDE-4718-8885-147AAE7C9439Q26853500-1E0235A6-7459-4C01-A787-1E374CC3C9E7Q27013917-3D00A922-8ADB-49CA-B996-E0D96B94C1D7Q27329756-D507C769-5E82-43FC-9397-D796D0B6B290Q27346473-0BF83B48-56F4-49F2-BAE9-E98AF2535868Q27469019-DD2267E1-ED03-4A01-973D-FFCCBDB79572Q27469038-45AE0192-A904-4742-B474-FE9B7F58F1E4Q27671640-71398F56-787C-4C2D-B60F-0374CCFF0CE2Q27672908-9FFA9C97-CFCF-48A4-B4D2-475B42D454CBQ27675615-3EEB8F15-B067-46BC-9805-588B55FF4D75Q27924226-C15EBFA6-DA8C-4366-9696-E1294B82F3AEQ28475468-22FEB616-C9CF-4CC3-AFF0-0CEF76D0B495Q28477175-BA688C0E-481C-493F-A973-459AF7F7D1A2Q28480947-AEFCD29D-D6DE-4160-998A-4936DC19E9ADQ28481038-E393A557-4F24-435B-9C9F-7326FC1E2808Q28481622-8ED7C692-AA28-47BE-B12A-1D1E00AEFCB7Q28488338-A6B43AC1-7413-483E-BDF1-7C0FEBB8D6FCQ28488372-1169EB64-24E7-4AE8-8FEA-4B791E1CF48DQ28538943-1AB9354D-7490-406E-A520-07553F3899B4Q28545971-011B511C-E14D-46C7-81D4-A897E2C33D0BQ28548426-587F5C84-81EA-4D97-9AEB-8AC82D07A59FQ28553112-EF54D2F6-69EE-4CD8-82E4-0AF460DA396CQ28553430-AB7AAAE5-E86B-4886-AF6E-431CD5977BB2Q28652352-854A4E29-3CA5-48C0-A3BD-E416C887957BQ28729744-335234F1-28E3-492F-BF19-A3E96F2E5B0AQ28742764-E020F1FC-E051-4EB7-BBBA-583A202BB9ADQ29417108-6B78EB5A-669D-4EB6-9FB1-4CE241356C3EQ30418339-FD9B3A87-DAA0-4E0C-998B-A37A6A1EF9EFQ30453975-D141FD29-AC0F-4878-89B8-A9A2118BBFB6Q30541731-0C27BDAC-AB64-4E72-ADC6-2A2B96D2A3B0Q33571517-DF971870-FA05-4CE9-A0BF-258B75A61702Q33602824-81AA7F85-9202-4BE8-8C07-D0B990DB5D03Q33648185-C12E1C78-49E0-4281-B72C-AF076441203E
P2860
Resistance to direct antiviral agents in patients with hepatitis C virus infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Resistance to direct antiviral agents in patients with hepatitis C virus infection.
@en
Resistance to direct antiviral agents in patients with hepatitis C virus infection.
@nl
type
label
Resistance to direct antiviral agents in patients with hepatitis C virus infection.
@en
Resistance to direct antiviral agents in patients with hepatitis C virus infection.
@nl
prefLabel
Resistance to direct antiviral agents in patients with hepatitis C virus infection.
@en
Resistance to direct antiviral agents in patients with hepatitis C virus infection.
@nl
P1433
P1476
Resistance to direct antiviral agents in patients with hepatitis C virus infection.
@en
P2093
Christoph Sarrazin
P304
P356
10.1053/J.GASTRO.2009.11.055
P407
P577
2009-12-16T00:00:00Z